Spots Global Cancer Trial Database for A Study of XMT-1660 in Participants With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of XMT-1660 in Participants With Solid Tumors
Official Title: A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Study ID: NCT05377996
Interventions
Study Description
Brief Summary: A Study of XMT-1660 in Solid Tumors
Detailed Description: This first-in-human (FIH) study will test the safety and side effects of a drug called XMT-1660. A side effect is anything a drug does to the body besides treating the disease. Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started (advanced) or spread through the body (metastatic). The study will have two parts. The first part called Dose Escalation will find out how much XMT-1660 should be given to participants. The second part called Dose Expansion will use the dose found in the first part to find out how safe XMT-1660 is and if it works to treat solid tumor cancers.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
UCLA, Santa Monica, California, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Health Hospital, Detroit, Michigan, United States
New York University Langone Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Stephenson Cancer Center Oklahoma University Health, Oklahoma City, Oklahoma, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Texas Oncology, P.A., Dallas, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
NEXT Oncology Virginia, Fairfax, Virginia, United States
Summit Cancer Centers, Spokane, Washington, United States
Contact Details
Name: Robert Burger, MD
Affiliation: Mersana Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
